Mesoblast Ltd ADR (MESO)
11.76  +1.38 (13.35%)

Mesoblast Ltd is a biotechnology company focused on developing innovative regenerative medicine therapies aimed at addressing significant unmet medical needs. Utilizing its expertise in cellular therapies, the company is advancing treatments for a range of conditions, including chronic inflammatory and degenerative diseases, as well as certain types of cancer. Mesoblast's pioneering work centers on the use of allogeneic cell products, derived from healthy donors, to harness the body’s natural healing processes, with the goal of improving patient outcomes and quality of life. Through rigorous clinical development programs, the company seeks to bring transformative therapies to market that can change the landscape of treatment for various critical health issues.

SummaryNewsPress ReleasesChartHistorical
Mesoblast Ltd. (NASDAQ: MESO) Near the Top of Equities by Percentage Gain on 4/1
Mesoblast Limited (NASDAQ: MESO) is one of today’s top gainers. The company’s shares have moved 30.62% on the day to $6.55.
Via Investor Brand Network · April 1, 2024
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK
Lately, several companies have captured investor attention due to remarkable gains. This article offers an in-depth analysis of five such companies worth tracking amid recent developments.
Via AB Newswire · March 28, 2024
Mesoblast Ltd. (NASDAQ: MESO) is One of Tuesday Morning’s Most Active Stocks
Mesoblast Limited (NASDAQ: MESO) is one today’s most active stocks by volume. So far today, approximately 29.43M shares of Mesoblast Limited have been exchanged, as compared to an average 30-day volume of 892.19k shares.
Via Investor Brand Network · March 26, 2024
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.
Via TheNewswire.com · October 14, 2022
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia among the elderly, accounting for between 60% and 80% of cases in the US, Japan and five major EU markets (the UK, Germany, France, Italy, and […]
Via FinancialNewsMedia · March 31, 2022
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in […]
Via FinancialNewsMedia · January 5, 2022